Clinical trials: Cetuximab, active
Cetuximab, Bioequivalence
A Randomized, Double-Blind, Positive-Controlled, Parallel Pharmacokinetic Phase I Clinical Study of Cetuximab Injection Versus Erbitux in Healthy Male Subjects
A Randomized, Double-Blind, Positive-Controlled, Parallel Pharmacokinetic Phase I Clinical Study of Cetuximab Injection versus Erbitux in Healthy Male Subjects
- Conditions
- Cetuximab, Bioequivalence, Healthy Volunteers, Pharmacokinetics
- Trial name
- BT-HC034S-101 (NCT07813468)
- Testing
- HC034S, Erbitux (Cetuximab)
- Where
- China
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- HC Biopharma Inc.
Colorectal Cancer, BRAF V600E Mutation Positive
A Single-Arm, Phase II, Multicenter Clinical Study of Neoadjuvant Encorafenib Plus Cetuximab N01 and mFOLFOX6 in Patients With Locally Advanced BRAF V600E-Mutant Colorectal Cancer With or Without Resectable Metastases
This is a single-arm, multicenter, phase II clinical trial evaluating the safety and efficacy of neoadjuvant encorafenib plus cetuximab N01 and mFOLFOX6 in patients with locally advanced BRAF V600E-mutated colorectal cancer, with…
- Conditions
- Colorectal Cancer, BRAF V600E Mutation Positive, Encorafenib, Cetuximab N01
- Trial name
- NEORAF (NCT07789210)
- Testing
- Neoadjuvant therapy of encorafenib plus cetuximab N01 and mFOLFOX6
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Zhejiang University
Colorectal Cancer, KRAS G12C Mutant Advanced Solid Tumors
Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases
Background：KRAS mutations are the most common genetic alterations in colorectal cancer (CRC), associated with aggressive tumor biology and poor prognosis.
- Conditions
- Colorectal Cancer, KRAS G12C Mutant Advanced Solid Tumors, Fulzerasib, Cetuximab N01
- Trial name
- FALCO (NCT07581912)
- Testing
- fulzerasib; cetuximab N01
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang University
BRAF V600E, Colorectal Cancer
A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer
Colorectal cancer (CRC) is the second leading cause of cancer-related death globally. BRAF V600E mutations occur in approximately 12% of metastatic CRC (mCRC) patients, conferring an extremely poor prognosis with a median overall…
- Conditions
- BRAF V600E, Colorectal Cancer, Sintilimab, MSS (Microsatellite Stable)
- Trial name
- NCT07506109
- Testing
- Ipilimumab N01, Sintilimab, Cetuximab
- Where
- 4 sites in China
- Volunteers
- 49 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Colorectal Neoplasms, RAS
The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer
Colorectal cancer is a malignant tumor ranking among the top four in incidence and the top three in causes of death globally . Chemotherapy combined with anti-EGFR or anti-VEGF monoclonal antibodies is currently the standard…
- Conditions
- Colorectal Neoplasms, RAS, BRAF, Cetuximabβ
- Trial name
- concept (NCT07257653)
- Testing
- Cetuximab β；Fruquintinib；, Cetuximab β；Fruquintinib；anti-PD1 antibody；, Cetuximab β；Fruquintinib；anti-PD1/CTLA4 antibody
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Zhejiang University
Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer
Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer
1. To verify that thalidomide can increase the efficacy of cetuximab plus chemotherapy in the treatment of stage IV RAS and BRAF wild-type unresectable left colorectal cancer, which has important clinical significance and…
- Trial name
- NCT06279351
- Testing
- Thalidomide+cetuximab+FOLFOX/FOLFIRI
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Xinqiao Hospital of Chongqing
Colorectal Cancer (CRC), Capecitabine
First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study
This multicenter, randomized, controlled, phase III study is conducted to evaluate the efficacy and safety of first line mCapOX plus Cetuximab versus mFOLFOX6 plus Cetuximab for RAS/BRAF wild-type, MSS, Unresectable Left-Sided…
- Conditions
- Colorectal Cancer (CRC), Capecitabine, Cetuximab
- Trial name
- CAPCET-III (NCT06616259)
- Testing
- mCapOX plus Cetuximab, mFOLFOX6 plus Cetuximab
- Where
- China
- Volunteers
- 452 people
- Sponsor
- Meng Qiu